You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
四環醫藥(00460.HK)完成利拉魯肽減肥適應症一期臨牀
格隆匯 02-26 12:18

格隆匯2月26日丨四環醫藥(00460.HK)宣佈,集團的利拉魯肽項目,開發適應症為2型糖尿病和肥胖的治療,目前已經完成了I期臨牀研究,並初步獲得了藥代動力學和藥效學的生物等效性結果。目前正在肥胖症III期開發計劃溝通中,不久將進入臨牀III期階段。

利拉魯肽(liraglutide)是一種胰高血糖素樣肽-1(GLP-1)激動劑,被美國食品藥品管理局批准用於治療成人及十歲以上的2型糖尿病患者,以及用於降低2型糖尿病患者心臟病發作、卒中及心血管死亡風險,此外,臨牀實驗中,利拉魯肽還顯示出減肥、改善肥胖相關合並症的潛力。

在中華人民共和國,由諾和諾德公司開發的Victoza(利拉魯肽)在2017年進入國家醫保目錄之後明顯放量,2019年收入達到人民幣9.26億元,同比增長70%。根據諾和諾德公司的披露,其利拉魯肽減肥產品Saxenda於2019年於全球實現了8.51億美元的銷售額,增長率為47%,該產品是拉動諾和諾德全球業績增長的主要因素。

集團的利拉魯肽產品目前預計將專注於中國市場。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account